Lumida
/PFE
⌘K
Pfizer Inc

Pfizer Inc

PFE
$27.72USD+0.25%+0.07 today

MARKET CAP

158.0B

P/E (TTM)

21.2x

FWD P/E

DAY RANGE

$27 – $28

52W RANGE

$24
$29

AI Summary

Stalk
StalkMedium

The chart remains in a healthy uptrend that is pausing into key support. Price is holding above the 20-day EMA and rising 50-day SMA, and pullbacks on light volume look constructive. Medium-term bias stays bullish while awaiting clear acceptance of support or a breakout above resistance. Tactical entries should be deferred until price confirms strength in the $26.25–$27.75 zone.

  • Q2 revenue $15B (+1% YoY; +5% ex-COVID) beats estimates, EPS $0.77.
  • Raised FY26 guidance to $60.5–62.5B after strong Q2 execution.
  • COVID revenue set to fall to ~$4B in 2026, reducing top-line growth.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$81.3B$101.2B$59.6B$63.6B$62.6B
YoY %+95.2%+24.5%-41.1%+6.8%-1.6%
P / Sales4.1x2.9x2.8x2.4x2.3x
EV / Sales5.4x3.9x5.1x4.3x4.2x
Gross Profit, Adj.$50.5B$66.8B$34.6B$45.8B$46.5B
YoY %+52.2%+32.4%-48.2%+32.3%+1.6%
Margin %62.1%66.1%58.1%71.9%74.3%
EV / Gross Profit8.7x5.9x8.8x6.0x5.6x
EBITDA, Adj.$28.9B$43.2B$10.7B$22.0B$24.0B
YoY %+103.6%+49.4%-75.2%+105.0%+9.3%
Margin %35.5%42.7%18.0%34.5%38.3%
EV / EBITDA15.2x9.1x28.4x12.5x10.9x
EBIT$19.4B$35.8B$1.3B$12.4B$14.2B
YoY %+135.6%+84.2%-96.4%+869.6%+14.8%
Margin %23.9%35.4%2.1%19.5%22.8%
EV / EBIT22.6x11.0x237.6x22.2x18.4x
Net Income$22.0B$31.4B$2.1B$8.0B$7.8B
YoY %+140.0%+42.7%-93.2%+279.0%-3.2%
Net Margin27.0%31.0%3.6%12.6%12.4%
EPS (GAAP)$3.85$5.47$0.37$1.41$1.36
YoY %+136.2%+42.1%-93.2%+281.1%-3.5%